S. Korea's Celltrion, Hospira Of U.S. Sign Biogeneric Marketing Pact
This article was originally published in PharmAsia News
Executive Summary
Celltrion of South Korea has signed an agreement with U.S.-based Hospira to collaborate on making and marketing eight of the South Korean firm's biogeneric products